TBC1D17

Across TCGA pan-cancer cohorts, TBC1D17 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of TBC1D17’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TBC1D17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TBC1D17 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

LIHC, BLCA, and KICH are the cancer types where TBC1D17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.035	<.001	9	view →
BLCA	Male	III,IV	−1.135	.001	8	view →
KICH	Male	All	−0.744	<.001	7	view →
UCEC	All	II,III,IV	−1.020	<.001	6	view →
LUAD	Male	All	−0.794	<.001	6	view →
BRCA	Female	II,III,IV	−0.514	<.001	6	view →
CHOL	Male	All	+1.033	<.001	5	view →
THCA	All	All	−0.176	.006	3	view →
KIRP	All	All	−0.270	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

TBC1D17–LIHC

Open the LIHC breakdown →